Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.91Last Year’s EPS
0.66Same Quarter Last Year
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -2.90%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales and profit growth, increased patient reach, and significant regulatory milestones. However, challenges with compounded GLP-1 drugs in the U.S., increased carbon emissions, and a reduced full-year outlook due to lower-than-planned penetration of branded GLP-1 treatments were notable lowlights.Company Guidance
During the Q1 2025 earnings call, Novo Nordisk highlighted several key metrics and strategic updates. The company reported an 18% increase in sales and a 20% growth in operating profit for the first three months of 2025. Novo Nordisk now serves nearly 46 million patients with its diabetes and obesity treatments, marking an increase of almost 4 million from the same period in 2024. However, total carbon emissions rose by 37%, primarily due to the acquisition of new production sites and expanded manufacturing capabilities. In terms of diversity, women now hold 42% of senior leadership positions, up from 41% the previous year. The company completed its pivotal REDEFINE 2 trial for CagriSema and is on track to submit for approval in the first quarter of 2026. Despite reducing the full-year outlook due to slower-than-anticipated GLP-1 uptake in the U.S., Novo Nordisk remains committed to expanding access through partnerships and initiatives with pharmacies and telehealth services. Sales in the U.S. grew by 17% while international operations saw a 19% increase, with obesity care sales growing 65% overall. The company is also closely monitoring potential U.S. tariffs but noted that current ones do not materially affect their 2025 financial outlook.Strong Sales and Operating Profit Growth
Novo Nordisk reported an 18% sales growth and a 20% operating profit growth for the first 3 months of 2025.
Increased Patient Reach
Serving nearly 46 million patients with diabetes and obesity treatments, an increase of almost 4 million compared to the first 3 months of 2024.
Wegovy Prescription Growth
Wegovy sales increased by 39% in U.S. operations in the first 3 months of 2025, driven by increased volumes.
Regulatory Milestones
The FDA accepted the application for Wegovy 2.4 mg for metabolic dysfunctional associated steatohepatitis with priority review, and the new drug application for oral Semaglutide 25 mg was submitted.
International Growth
Sales in International Operations grew by 19%, driven by GLP-1 products with Obesity care sales growing by 137%.
---
NVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $66.29 | $67.55 | +1.90% |
Feb 05, 2025 | $81.68 | $84.76 | +3.77% |
Nov 06, 2024 | $108.88 | $104.16 | -4.34% |
Aug 07, 2024 | $128.30 | $117.56 | -8.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novo Nordisk (NVO) report earnings?
Novo Nordisk (NVO) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Novo Nordisk (NVO) earnings time?
Novo Nordisk (NVO) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVO EPS forecast?
NVO EPS forecast for the fiscal quarter 2025 (Q2) is 0.91.
---
